INT49313

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 1995
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 9.55
Pain Relevance 2.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apoa1) transport (Apoa1) extracellular space (Apoa1)
extracellular region (Apoa1) nucleus (Apoa1) enzyme binding (Apoa1)
Apoa1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Multiple sclerosis 192 99.84 Very High Very High Very High
rheumatoid arthritis 68 99.56 Very High Very High Very High
lidocaine 1 91.44 High High
pruritus 3 73.04 Quite High
nud 1 65.44 Quite High
Inflammation 36 62.72 Quite High
cytokine 32 61.68 Quite High
Central nervous system 28 5.00 Very Low Very Low Very Low
Neuritis 8 5.00 Very Low Very Low Very Low
Demyelination 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 71 100.00 Very High Very High Very High
Hepatotoxicity 3 99.92 Very High Very High Very High
Demyelinating Disease 236 99.84 Very High Very High Very High
Rheumatoid Arthritis 68 99.56 Very High Very High Very High
Disease 42 98.08 Very High Very High Very High
Systemic Lupus Erythematosus 76 97.60 Very High Very High Very High
Syndrome 56 97.60 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

12 96.56 Very High Very High Very High
Experimental Autoimmune Encephalomyelitis 8 95.56 Very High Very High Very High
Coronary Artery Disease 2 94.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Similar to the Shore ea al, our research showed increased serum apoA-I levels in MS patients and other autoimmune demyelinating disease (CIS, GBS) whether male and female patients.
Spec (whether) Positive_regulation (increased) of Spec (whether) Gene_expression (levels) of apoA-I associated with multiple sclerosis, syndrome and demyelinating disease
1) Confidence 0.68 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 2.10 Pain Relevance 0.61
For male patients (Table 2), male MS patients (1.263 ± 0.075 g/L) had significantly higher serum apoA-I levels than male RA patients (0.963 ± 0.102 g/L; P = 0.000), male SLE patients (0.979 ± 0.106 g/L; P = 0.000) and male healthy subjects(1.112 ± 0.070 g/L; P = 0.001) (Figure 2).
Positive_regulation (serum) of Gene_expression (levels) of apoA-I associated with multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus
2) Confidence 0.49 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.86 Pain Relevance 0.38
For male patients (Table 2), male MS patients (1.263 ± 0.075 g/L) had significantly higher serum apoA-I levels than male RA patients (0.963 ± 0.102 g/L; P = 0.000), male SLE patients (0.979 ± 0.106 g/L; P = 0.000) and male healthy subjects(1.112 ± 0.070 g/L; P = 0.001) (Figure 2).
Positive_regulation (higher) of Gene_expression (levels) of apoA-I associated with multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus
3) Confidence 0.49 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.86 Pain Relevance 0.38
The results showed that serum apoA-I levels was much higher in female MS patients (1.523 ± 0.082 g/L) and female RA patients (1.120 ± 0.042 g/L) than the corresponding male MS patients (1.262 ± 0.087 g/L; P = 120.033) and male RA patients (0.948 ± 0.049 g/L; P = 120.012) (Figure 3).


Positive_regulation (higher) of Gene_expression (levels) of apoA-I associated with multiple sclerosis and rheumatoid arthritis
4) Confidence 0.49 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.69 Pain Relevance 0.44
Apo AI levels fell in both groups to day 5, but then began to increase in the group with good hepatic function, a highly significant (P < 0.001) positive correlation being found with the results of the MEGX test on post-transplant days 7, 10 and 14.
Positive_regulation (increase) of Gene_expression (levels) of Apo AI
5) Confidence 0.18 Published 1995 Journal Eur. J. Clin. Invest. Section Abstract Doc Link 7556366 Disease Relevance 0.34 Pain Relevance 0.09
Lovastatin and niacin in low doses used in the present study resulted in a significant decline in LDL cholesterol, triglycerides, and lp(a) along with an increase in HDL cholesterol and apoA1/apoB ratio.
Positive_regulation (increase) of Gene_expression (ratio) of apoA1 associated with disorder of lipid metabolism
6) Confidence 0.09 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993969 Disease Relevance 1.34 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox